Abvc Biopharma (ABVC) Net Income (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Net Income came in at -$1.3 million in Q1 2026, down 78.93% YoY from -$6.3 million in Q1 2025, and up 55.74% on a QoQ basis from -$3.0 million in Q4 2025.
Abvc Biopharma (ABVC) Net Income (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 16 years of Net Income data on file, last reported at -$1.3 million in Q1 2026.
- Quarterly Net Income fell 78.93% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.8 million (down 184.9% YoY) and the FY2025 annual result came in at -$8.4 million, down 59.29% from the prior year.
- Net Income grew to -$1.3 million in Q1 2026, from -$3.0 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$487431.0 in Q3 2024 to a low of -$6.1 million in Q1 2022.
- A 5-year average of -$2.3 million and a median of -$2.1 million in 2025 frame the typical range for Net Income.
- Annual changes were most pronounced in 2022 — Net Income sank 409.29% — and 2024, when it surged 85.53%.
- Tracing ABVC's Net Income over 5 years: stood at -$4.3 million in 2022, then soared by 83.84% to -$700309.0 in 2023, then fell by 13.74% to -$796527.0 in 2024, then plunged by 278.7% to -$3.0 million in 2025, then soared by 55.74% to -$1.3 million in 2026.
- The last three Net Income figures came in at -$1.3 million (Q1 2026), -$3.0 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | -640,280.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -640,280.00 |
| Mar 31, 2026 | -1.34 Mn |
| Dec 31, 2025 | -3.02 Mn |
| Sep 30, 2025 | -2.08 Mn |
| Jun 30, 2025 | -2.33 Mn |
| Mar 31, 2025 | -746,119.00 |
| Dec 31, 2024 | -796,527.00 |
| Sep 30, 2024 | -487,431.00 |
| Jun 30, 2024 | -1.05 Mn |
| Mar 31, 2024 | -2.93 Mn |
| Dec 31, 2023 | -700,309.00 |
| Sep 30, 2023 | -3.37 Mn |
| Jun 30, 2023 | -2.32 Mn |
| Mar 31, 2023 | -1.90 Mn |
| Dec 31, 2022 | -4.33 Mn |
| Sep 30, 2022 | -3.78 Mn |
| Jun 30, 2022 | -1.95 Mn |
| Mar 31, 2022 | -6.09 Mn |
| Dec 31, 2021 | -6.90 Mn |
| Sep 30, 2021 | -1.89 Mn |